Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
A clinical-stage biotech building engineered antibody drugs that activate immune targets, with two lead candidates in trials for cancer and rare diseases.
No revenue yet; the business burns cash, with annual operating losses around USD 0.14B in 2025 and net losses of USD 0.24B in 2023.
Proprietary modular protein engineering platforms enable tailored drug designs, but with no approved products, competitors like Amgen and Roche can replicate similar approaches.
